Cyclacel Pharmaceuticals (CYCC) announced that it has received a letter from Nasdaq, informing the company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC: